Cabaletta Bio Reports First Quarter 2021 Financial Results and Provides New Pipeline Updates
May 03, 2021 07:05 ET
|
Cabaletta Bio
– Acute safety data from the first cohort in the DesCAARTes™ trial announced today; no dose limiting toxicities (DLTs) or clinically relevant adverse events observed in the first dose cohort as of...
Cabaletta Bio Reports Acute Safety Data from the First Dose Cohort in DesCAARTes™ Trial
May 03, 2021 07:00 ET
|
Cabaletta Bio
– No dose limiting toxicities (DLTs) or clinically relevant adverse events observed in the first dose cohort as of April 30, 2021 – – Second dose cohort to be initiated after the third patient...
Cabaletta Bio to Present at the 20th Annual Needham Healthcare Conference
April 07, 2021 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, April 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies...
Cabaletta Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Business Update
March 16, 2021 07:30 ET
|
Cabaletta Bio
PHILADELPHIA, March 16, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies...
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
February 23, 2021 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
Cabaletta Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 07, 2021 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
Cabaletta Bio to Participate in Upcoming January Investor Conferences
January 04, 2021 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
Cabaletta Bio Announces First Patient Dosed in Landmark DesCAARTes™ Trial of DSG3-CAART for Treatment of Mucosal-Dominant Pemphigus Vulgaris
December 08, 2020 16:30 ET
|
Cabaletta Bio
First patient ever infused with a CAAR (chimeric autoantibody receptor) T cell therapy product candidate expands the potential clinical application of CAR T technology beyond cancer into autoimmune...
Cabaletta Bio to Participate in Upcoming December Investor Conferences
November 23, 2020 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
Cabaletta Bio Reports Third Quarter 2020 Financial Results and Provides Business Update
November 10, 2020 07:30 ET
|
Cabaletta Bio
PHILADELPHIA, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...